Clinical trial
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase…
NCT00147485 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00147485 |
|---|---|
| Title | A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer |
| Official title | A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of AG-024322, An Inhibitor Of Cyclin-Dependent Kinase 1, 2 And 4, Administered Intravenously Daily For 5 Days Every 3 Weeks To Patients With Advanced Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | AG-024322 |
| Enrollment | 37 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Sep 7, 2005 |
| Last update posted | Aug 18, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: